Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.
about
Bone as an endocrine organPartial agonist, telmisartan, maintains PPARγ serine 112 phosphorylation, and does not affect osteoblast differentiation and bone massThe Bone Marrow-Derived Stromal Cells: Commitment and Regulation of AdipogenesisRecognizing and treating secondary osteoporosisMedical Management of Diabesity: Do We Have Realistic Targets?Osteoporosis piece of multi-morbidity puzzle in geriatric care.Diabetes, bone and glucose-lowering agents: basic biology.Bone marrow fat has brown adipose tissue characteristics, which are attenuated with aging and diabetes.Minireview: nuclear receptor regulation of osteoclast and bone remodeling.Republished: Non-alcoholic fatty liver disease: a practical approach to treatment.Thiazolidinediones on PPARγ: The Roles in Bone Remodeling.Management of diabetes across the course of disease: minimizing obesity-associated complicationsGlycemic Control with Thiazolidinedione Is Associated with Fracture of T2DM Patients.Fracture incidence and risk of osteoporosis in female type 2 diabetic patients in Korea.Pathophysiological role of enhanced bone marrow adipogenesis in diabetic complications.Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs.Rheumatic manifestations in diabetic patientsReciprocal Control of Osteogenic and Adipogenic Differentiation by ERK/MAP Kinase Phosphorylation of Runx2 and PPARγ Transcription Factors.Glucose and low-density lipoprotein cholesterol lowering in elderly patients with type 2 diabetes: focus on combination therapy with colesevelam HCl.Safety of Anti-Diabetic Therapies on Bone.Rosiglitazone inhibits bone regeneration and causes significant accumulation of fat at sites of new bone formation.Hyperglycemia induces endoplasmic reticulum stress-dependent CHOP expression in osteoblasts.VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease.Causes, consequences, and treatment of osteoporosis in men.The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healing.All-trans retinoic acid shifts rosiglitazone-induced adipogenic differentiation to osteogenic differentiation in mouse embryonic fibroblasts.The effects of rosiglitazone on osteoblastic differentiation, osteoclast formation and bone resorption.Fracture Risk in Type 2 Diabetes: Current Perspectives and Gender DifferencesMelatonin-micronutrients Osteopenia Treatment Study (MOTS): a translational study assessing melatonin, strontium (citrate), vitamin D3 and vitamin K2 (MK7) on bone density, bone marker turnover and health related quality of life in postmenopausal osTransitioning from inpatient to outpatient therapy in patients with in-hospital hyperglycemia.Potential drug interactions associated with treatments for type 2 diabetes and its comorbidities: a clinical pharmacology review.Diabetes and fracture healing: the skeletal effects of diabetic drugs.There are many potential medical therapies for atraumatic osteonecrosis.Diabetes mellitus and inflammatory pulpal and periapical disease: a review.Diabetes mellitus and osteoporosis.Adipocytes and the regulation of bone remodeling: a balancing act.Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategies.Review article: new treatments in non-alcoholic fatty liver disease.Non-alcoholic fatty liver disease in 2016.Vitamin D Level Between Calcium-Phosphorus Homeostasis and Immune System: New Perspective in Osteoporosis.
P2860
Q27010173-81CD9FC0-D10C-42A3-8ADC-387F5FA8EA2FQ27334866-D9C9F2F4-1E63-44EF-9D63-715E5BC0AC28Q28078585-B99EF62C-0693-418E-940A-06A802CF31F8Q28270738-B57D2041-3B8F-4FB5-B675-0EFF72C90DF5Q30238940-909215B6-805C-4CC8-8974-2F5E43639ABDQ33351754-A7860A8E-D1DC-421F-8301-B0990F278D98Q33843692-6754788D-D857-42F9-BF23-C0F1F926B57AQ34197048-F0A6AB40-9EC6-412E-9CF3-8EDCC04A9BE5Q35054970-92E7B0EF-241A-4DD9-9A82-CC9138B5E4CEQ35135556-1102552E-61F8-44D8-838B-049E92D95EFFQ35496098-289167F9-4F96-44AA-B268-88C5E4FF4608Q35574560-4C2D0C4E-4F45-4C18-A018-E496BB5C73ADQ35759258-8275A67F-E358-485D-B3CF-C77D8B1DD0A1Q35911081-76BDB809-244D-4103-8531-8788C024EE38Q35998796-4A438C88-C531-4C2B-8B32-77142E18321DQ36297873-1377FEC7-1161-4E7F-B54A-BEA87190C725Q36299797-05B1FB9C-9374-463F-B331-A22245607D39Q36558095-CE089B5C-84B6-4DC3-9A67-8B6366D553B7Q36649815-4FF965A3-F7DC-4B57-BE0C-55274C532A5BQ36716222-5ED6F333-353E-411D-9C98-0A2FFE47702DQ36779975-F20887B9-7F2B-4C56-A2EA-85F9654CA748Q36900471-EA1D060D-38BE-4FB4-9808-274FB4537FA8Q37105051-2C622362-2463-420F-848E-D5635BDC1930Q37134718-591AB800-5579-4D00-BBC1-8744A268BC2FQ37182800-CEBC1919-D686-4718-891D-CAE2B988A6D2Q37426679-BAA7255A-6AA2-45CA-B8C2-0DEC15A4E1B3Q37461510-8AE7FE56-E20E-4588-8B3E-CF31B69153C6Q37511845-3BFA45C8-0C3A-4957-B0A6-26C3D8C7BF85Q37643521-25738027-779D-4EBF-B213-A699666DC378Q37953155-574EC708-8B00-44F6-AE51-54668774F7F0Q37964751-E1C82A75-1528-4904-AC29-DF895CC1EA51Q37965266-E6E21FCB-1453-42EA-B9DB-B33339CF1E2DQ38049949-B9A4703D-7F9B-4AD7-9511-295AAA91FB39Q38084724-D2B0D9AD-D46B-4A9F-BE0D-A970C64109A8Q38087556-974EC286-F043-4E3D-A86E-CE31C39F68D2Q38150258-BF570DD5-8DBE-4857-AAC8-55AE2082CED3Q38442816-786EA494-F058-4F69-9083-DCF042ABED1BQ38662765-DC68E3E5-0041-4BA3-9B86-8FBE4C9C86C7Q38932554-FC6A9D0A-727F-4548-BFD2-651B9DF5DD15Q38979293-53F49D3B-C7DE-4612-84AE-0DF4620CF6D1
P2860
Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.
@ast
Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.
@en
Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.
@nl
type
label
Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.
@ast
Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.
@en
Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.
@nl
prefLabel
Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.
@ast
Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.
@en
Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.
@nl
P2860
P921
P1476
Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.
@en
P2093
Beata Lecka-Czernik
P2860
P2888
P304
P356
10.1007/S11914-010-0027-Y
P577
2010-12-01T00:00:00Z
P5875
P6179
1011800527